Corium International (CORI) Given a $14.00 Price Target at HC Wainwright

Corium International (NASDAQ:CORI) has been given a $14.00 price target by equities researchers at HC Wainwright in a report issued on Wednesday, December 27th, MarketBeat reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 25.34% from the company’s previous close.

CORI has been the topic of a number of other research reports. Zacks Investment Research upgraded Corium International from a “sell” rating to a “hold” rating in a research report on Tuesday, November 28th. Needham & Company LLC increased their price objective on Corium International from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, November 20th. Cantor Fitzgerald reissued a “buy” rating and set a $14.00 target price on shares of Corium International in a research note on Friday, December 22nd. Jefferies Group set a $10.00 target price on Corium International and gave the company a “buy” rating in a research note on Sunday, October 29th. Finally, ValuEngine upgraded Corium International from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. Corium International currently has an average rating of “Buy” and an average target price of $12.86.

Corium International (NASDAQ:CORI) opened at $11.17 on Wednesday. Corium International has a fifty-two week low of $2.67 and a fifty-two week high of $12.32. The company has a debt-to-equity ratio of 2.41, a current ratio of 2.70 and a quick ratio of 2.60. The firm has a market cap of $407.47, a price-to-earnings ratio of -6.69 and a beta of 1.26.

In other Corium International news, major shareholder Healthcare Master Fun Broadfin sold 500,000 shares of the business’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $10.96, for a total transaction of $5,480,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 45.70% of the stock is currently owned by insiders.

Several institutional investors have recently made changes to their positions in CORI. Stonepine Capital Management LLC acquired a new stake in shares of Corium International during the 2nd quarter worth approximately $3,085,000. State Street Corp bought a new position in Corium International during the 2nd quarter valued at $1,840,000. EAM Investors LLC acquired a new stake in shares of Corium International during the 2nd quarter valued at $563,000. TIAA CREF Investment Management LLC acquired a new stake in shares of Corium International during the 2nd quarter valued at $411,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Corium International by 161.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 66,160 shares of the biopharmaceutical company’s stock valued at $494,000 after acquiring an additional 40,891 shares during the last quarter. Institutional investors and hedge funds own 89.08% of the company’s stock.

WARNING: “Corium International (CORI) Given a $14.00 Price Target at HC Wainwright” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/12/corium-international-cori-given-a-14-00-price-target-by-hc-wainwright-analysts-2.html.

About Corium International

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Analyst Recommendations for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply